Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment

Published:2021-12 Issue: Volume:30 Page:100301
ISSN:2213-5383
Container-title:Journal of Cancer Policy
language:en
Short-container-title:Journal of Cancer Policy

Author:

Robinson Andrew G.^ORCID,O’Donnell Jennifer,Booth Christopher,Koven Rachel,Eisenhauer Elizabeth,Brundage Michael^ORCID

Funder

Merck

Publisher

Elsevier BV

Subject

Health Policy,Oncology

Reference10 articles.

1. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice;Robinson;Eur. J. Cancer,2014

2. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials;Giessen;Clin. Cancer Res.,2013

3. A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model;Stewart;Crit. Rev. Oncol. Hematol.,2020

4. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis;Kovic;JAMA Intern. Med.,2018

5. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review;Belin;Br. J. Cancer,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed;Nature Reviews Clinical Oncology;2023-10-12

2. Advances and Challenges in Trials of Local Therapy for Patients With Oligometastatic or Oligoprogressive Disease;Seminars in Radiation Oncology;2023-10

3. Patients’ attitudes and preferences toward delayed disease progression in the absence of improved survival;JNCI: Journal of the National Cancer Institute;2023-07-17

4. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC);Journal for ImmunoTherapy of Cancer;2022-09

5. Patient-centered trials in oncology: Time for a change;Med;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3